{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:07:58Z","timestamp":1791313678325,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81520108003"],"award-info":[{"award-number":["81520108003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830007"],"award-info":[{"award-number":["81830007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670176"],"award-info":[{"award-number":["81670176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700191"],"award-info":[{"award-number":["81700191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["16JC1405800"],"award-info":[{"award-number":["16JC1405800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support","award":["20152206"],"award-info":[{"award-number":["20152206"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["20152208"],"award-info":[{"award-number":["20152208"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","award":["16CR2017A"],"award-info":[{"award-number":["16CR2017A"]}],"id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["DLY201601"],"award-info":[{"award-number":["DLY201601"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Innovation Center for Systems Biomedicine","award":["\/"],"award-info":[{"award-number":["\/"]}]},{"DOI":"10.13039\/100001384","name":"Samuel Waxman Cancer Research Foundation","doi-asserted-by":"publisher","award":["\/"],"award-info":[{"award-number":["\/"]}],"id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Multicenter Hematology-Oncology Programs Evaluation System","award":["\/"],"award-info":[{"award-number":["\/"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)\/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Here we conducted a phase 2, multicenter, randomized, controlled trial, comparing the efficacy and safety of CEOP\/IVE\/GDP alternating regimen with CEOP in newly diagnosed PTCL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>PTCL patients, except for anaplastic large cell lymphoma-anaplastic lymphoma kinase positive, were 1:1 randomly assigned to receive CEOP\/IVE\/GDP (CEOP, cyclophosphamide 750\u2009mg\/m<jats:sup>2<\/jats:sup>, epirubicin 70\u2009mg\/m<jats:sup>2<\/jats:sup>, vincristine 1.4\u2009mg\/m<jats:sup>2<\/jats:sup> [maximum 2\u2009mg] on day 1, and prednisone 60\u2009mg\/m<jats:sup>2<\/jats:sup> [maximum 100\u2009mg] on days 1\u20135 every 21\u2009days, at the first and fourth cycle; IVE, ifosfamide 2000\u2009mg\/m<jats:sup>2<\/jats:sup> on days 1\u20133, epirubicin 70\u2009mg\/m<jats:sup>2<\/jats:sup> on day 1, and etoposide 100\u2009mg\/m<jats:sup>2<\/jats:sup> on days 1\u20133 every 21\u2009days, at the second and fifth cycle; and GDP, gemcitabine 1000\u2009mg\/m<jats:sup>2<\/jats:sup> on days 1 and 8, cisplatin 25\u2009mg\/m<jats:sup>2<\/jats:sup> on days 1\u20133, and dexamethasone 40\u2009mg on days 1\u20134 every 21\u2009days, at the third and sixth cycle) and CEOP (every 21\u2009days for 6\u2009cycles). Analysis of efficacy and safety was of the intent-to-treatment population. The primary endpoint was a complete response rate at the end of treatment. Meanwhile, whole exome sequencing and targeted sequencing were performed in 62 patients with available tumor samples to explore prognostic biomarkers in this cohort as an exploratory post hoc analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 106 patients, 53 each were enrolled to CEOP\/IVE\/GDP and CEOP. With 51 evaluable patients each in two groups, a complete response rate of the CEOP\/IVE\/GDP group was similar to that of the CEOP group (37.3% vs. 31.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.532). There was no difference in median progression-free survival (PFS; 15.4\u2009months vs. 9.2\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.122) or overall survival (OS; 24.3\u2009months vs. 21.9\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.178). Grade 3\u20134 hematological and non-hematological adverse events were comparable. Histone modification genes were most frequently mutated (25\/62, 40.3%), namely <jats:italic>KMT2D<\/jats:italic>, <jats:italic>KMT2A<\/jats:italic>, <jats:italic>SETD2<\/jats:italic>, <jats:italic>EP300<\/jats:italic>, and <jats:italic>CREBBP<\/jats:italic>. Multivariate analysis indicated that <jats:italic>CREBBP<\/jats:italic> and <jats:italic>IDH2<\/jats:italic> mutations were independent factors predicting poor PFS and OS (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), while <jats:italic>KMT2D<\/jats:italic> predicting poor PFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>CEOP\/IVE\/GDP alternating regimen showed no remission or survival advantage to standard chemotherapy. Future clinical trials should aim to develop alternative regimen targeting disease biology as demonstrated by recurrent mutations in epigenetic factors.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>The study was registered on ClinicalTrial.gov (NCT02533700) on August 27, 2015.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13073-020-00739-0","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T23:05:36Z","timestamp":1588201536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Ming-Ci","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Da","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Sheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Meng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"issue":"5","key":"739_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/ajh.23684","volume":"89","author":"M Hertzberg","year":"2014","unstructured":"Hertzberg M, et al. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. Am J Hematol. 2014;89(5):536\u201341.","journal-title":"Am J Hematol"},{"issue":"25","key":"739_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, et al. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.","journal-title":"ISRN Hematol"},{"issue":"9","key":"739_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/10245332.2016.1152084","volume":"21","author":"B Jia","year":"2016","unstructured":"Jia B, et al. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology. 2016;21(9):536\u201341.","journal-title":"Hematology"},{"issue":"1","key":"739_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3960\/jslrt.56.50","volume":"56","author":"A Fukunaga","year":"2016","unstructured":"Fukunaga A, et al. Dose-modified ifosfamide, epirubicin, and etoposide is a safe and effective salvage therapy with high peripheral blood stem cell mobilization capacity for poorly mobilized Hodgkin's lymphoma and non-Hodgkin's lymphoma patients. J Clin Exp Hematop. 2016;56(1):50\u20134.","journal-title":"J Clin Exp Hematop"},{"issue":"Suppl 1","key":"739_CR6","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/annonc\/mdg709","volume":"14","author":"PL Zinzani","year":"2003","unstructured":"Zinzani PL. Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience. Ann Oncol. 2003;14(Suppl 1):i43\u20135.","journal-title":"Ann Oncol"},{"issue":"8","key":"739_CR7","first-page":"816","volume":"87","author":"PL Zinzani","year":"2002","unstructured":"Zinzani PL, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed\/refractory lymphoma patients. Haematologica. 2002;87(8):816\u201321.","journal-title":"Haematologica"},{"key":"739_CR8","first-page":"28","volume":"64","author":"SJ Proctor","year":"2001","unstructured":"Proctor SJ, et al. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed\/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Eur J Haematol Suppl. 2001;64:28\u201332.","journal-title":"Eur J Haematol Suppl"},{"issue":"Suppl 1","key":"739_CR9","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1093\/annonc\/mdg710","volume":"14","author":"SJ Proctor","year":"2003","unstructured":"Proctor SJ, et al. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol. 2003;14(Suppl 1):i47\u201350.","journal-title":"Ann Oncol"},{"issue":"5","key":"739_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2141.2007.06498.x","volume":"136","author":"MJ Bishton","year":"2007","unstructured":"Bishton MJ, et al. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol. 2007;136(5):752\u201361.","journal-title":"Br J Haematol"},{"issue":"18","key":"739_CR11","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","volume":"115","author":"M Sieniawski","year":"2010","unstructured":"Sieniawski M, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664\u201370.","journal-title":"Blood"},{"issue":"4","key":"739_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3324\/haematol.2017.182444","volume":"103","author":"MM Ji","year":"2018","unstructured":"Ji MM, et al. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103(4):679\u201387.","journal-title":"Haematologica"},{"issue":"2","key":"739_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370.","journal-title":"Nat Genet"},{"issue":"Supplement_1","key":"739_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood-2019-122369","volume":"134","author":"M Cai","year":"2019","unstructured":"Cai M, et al. CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T-cell lymphoma: results from a phase 2, multi-center, randomized, controlled clinical trial. Blood. 2019;134(Supplement_1):1556.","journal-title":"Blood"},{"key":"739_CR15","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revsied 4th Edition","author":"WHO","year":"2016","unstructured":"WHO, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revsied 4th Edition. 2016."},{"key":"739_CR16","doi-asserted-by":"publisher","unstructured":"Cai M, et al. CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T-cell lymphoma: results from a phase 2, multi-center, randomized, controlled clinical trial: Mendeley; 2020. https:\/\/doi.org\/10.17632\/jcp3kc4tzx.1.","DOI":"10.17632\/jcp3kc4tzx.1"},{"key":"739_CR17","unstructured":"Cai M, et al. CEOP\/IVE\/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T-cell lymphoma: results from a phase 2, multi-center, randomized, controlled clinical trial. NODE. OEP000795. 2020. http:\/\/www.biosino.org\/node\/project\/detail\/OEP000795. Accessed 14 Mar 2020."},{"issue":"27","key":"739_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"4","key":"739_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860\u20133.","journal-title":"Ann Oncol"},{"issue":"1","key":"739_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","volume":"30","author":"M Dong","year":"2013","unstructured":"Dong M, et al. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol. 2013;30(1):351.","journal-title":"Med Oncol"},{"issue":"5","key":"739_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14763","volume":"178","author":"L Li","year":"2017","unstructured":"Li L, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol. 2017;178(5):772\u201380.","journal-title":"Br J Haematol"},{"issue":"1","key":"739_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-018-3488-1","volume":"98","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, et al. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. Ann Hematol. 2019;98(1):143\u201350.","journal-title":"Ann Hematol"},{"issue":"5","key":"739_CR23","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","volume":"5","author":"M Gleeson","year":"2018","unstructured":"Gleeson M, et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018;5(5):e190\u2013200.","journal-title":"Lancet Haematol"},{"issue":"22","key":"739_CR24","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1182\/blood.V114.22.1956.1956","volume":"114","author":"C Casulo","year":"2009","unstructured":"Casulo C, et al. Negative interim FDG-PET scan is predictive of superior outcome in T cell lymphoma. Blood. 2009;114(22):1956.","journal-title":"Blood"},{"issue":"9","key":"739_CR25","first-page":"772","volume":"38","author":"MC Zhang","year":"2017","unstructured":"Zhang MC, et al. Prognostic significance of NCCN-international prognostic index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Zhonghua Xue Ye Xue Za Zhi. 2017;38(9):772\u20137.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"10","key":"739_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/15384047.2019.1638670","volume":"20","author":"LM Gao","year":"2019","unstructured":"Gao LM, et al. Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders. Cancer Biol Ther. 2019;20(10):1319\u201327.","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"739_CR27","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/leu.2016.135","volume":"30","author":"D Juskevicius","year":"2016","unstructured":"Juskevicius D, et al. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30(12):2385\u201395.","journal-title":"Leukemia"},{"issue":"1","key":"739_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-017-0438-7","volume":"10","author":"D Juskevicius","year":"2017","unstructured":"Juskevicius D, et al. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38\/07 prospective clinical trial cohort. J Hematol Oncol. 2017;10(1):70.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"739_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2013-10-533604","volume":"125","author":"A Kernytsky","year":"2015","unstructured":"Kernytsky A, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015;125(2):296\u2013303.","journal-title":"Blood"},{"issue":"4","key":"739_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","volume":"7","author":"M McKinney","year":"2017","unstructured":"McKinney M, et al. The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov. 2017;7(4):369\u201379.","journal-title":"Cancer Discov"},{"key":"739_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1752-0509-7-25","volume":"7","author":"V Trifonov","year":"2013","unstructured":"Trifonov V, et al. MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples. BMC Syst Biol. 2013;7:25.","journal-title":"BMC Syst Biol"},{"issue":"17","key":"739_CR32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O'Connor","year":"2019","unstructured":"O'Connor OA, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395\u2013405.","journal-title":"Blood"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-020-00739-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-020-00739-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-020-00739-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T23:25:37Z","timestamp":1619738737000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-020-00739-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1186\/s13073-020-00739-0","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee on May 11, 2015, in Shandong Province Hospital Ethics Committee (No. 2015-10), registered and approved by the clinicaltrial.gov. on August 27, 2015. The study was also approved by the Institutional Review Boards of the other participating study centers: Shanghai Rui Jin Hospital, Fujian Medical University Union Hospital, and the Affiliated Cancer Hospital of Zhengzhou University. The first patient was enrolled in September 22, 2015. Informed consent was obtained from all patients prior to enrollment and the study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}